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MitochondriaRecent evidence highlights monoamine oxidases (MAO) as another prominent source of oxidative stress.
MAO are a class of enzymes located in the outer mitochondrial membrane, deputed to the oxidative
breakdown of key neurotransmitters such as norepinephrine, epinephrine and dopamine, and in the
process generate H2O2. All these monoamines are endowed with potent modulatory effects on
myocardial function. Thus, when the heart is subjected to chronic neuro-hormonal and/or peripheral
hemodynamic stress, the abundance of circulating/tissue monoamines can make MAO-derived H2O2
production particularly prominent. This is the case of acute cardiac damage due to ischemia/reperfusion
injury or, on a more chronic stand, of the transition from compensated hypertrophy to overt ventricular
dilation/pump failure. Here, we will ﬁrst brieﬂy discuss mitochondrial status and contribution to acute
and chronic cardiac disorders. We will illustrate possible mechanisms by which MAO activity affects
cardiac biology and function, along with a discussion as to their role as a prominent source of reactive
oxygen species. Finally, we will speculate on why MAO inhibition might have a therapeutic value for
treating cardiac affections of ischemic and non-ischemic origin. This article is part of a Special Issue
entitled: Mitochondria and Cardioprotection.ignal-regulating kinase 1; AT,
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Given its “highly-aerobic” mode of operation, the cardiac muscle
is tightly dependent on oxidative energy supplied by mitochondria
via fatty acid (FA) β-oxidation, electron transport chain and
oxidative phosphorylation. Mitochondrial energy production
depends on genetic factors that modulate normal mitochondrial
function including enzyme activity and cofactor availability, and by
environmental variables, such as the availability of fuels (i.e. sugars,
fats and proteins) and oxygen.
In the postnatal and adult heart, FAs are the primary energy
substrate for ATP generation via oxidative phosphorylation and themitochondrial respiratory chain, the most important source of cardiac
energy [1–3]. Over 75% of the ATP produced via mitochondrial
oxidative phosphorylation is used to support myocyte contractile
activity. To this purpose, mitochondria appear to be clustered at sites
of high ATP demand and are organized into highly ordered elongated
bundles, regularly spaced between rows of myoﬁlaments and in
contact with the sarcoplasmic reticulum.
Thus, preserving mitochondrial function, and protecting it from
noxae, is essential for myocardial cells to cope with increased
workload and stresses of diverse origin. Moreover, mitochondria
participate in intracardiac Ca2+ handling and homeostasis. Therefore,
targeting mitochondrial dysfunction is increasingly appreciated as a
new attractive avenue to correct redox and/or metabolic aspects of
human cardiac disorders.1.1. Mitochondrial functional disarray and cardiac disorders
Given its dependence on mitochondrial bioenergetics and metab-
olism, the cardiac muscle is especially vulnerable to mitochondrial
derangements [4,5]. Insufﬁcient cellular oxygenation leads to the
inhibition of electron ﬂow through the respiratory chain and
consequently, an impairment of energy conservation and oxidative
metabolism. The impairment of respiratory chain function prevents
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loss in protonmotive force composed of membrane potential and
proton gradient. If the latter is not generated, F1F0ATP synthase may
function in a “reverse mode” thereby coupling ATP hydrolysis with
proton pumping to maintain the mitochondrial membrane potential.
The net result will be that themitochondria will cease to represent the
main source of intracellular ATP and become very powerful in
hydrolyzing glycolytically produced ATP [6]. Further to this, mito-
chondrial Ca2+ homeostasis is also hampered. This typically occurs in
ischemia/reperfusion (I/R) injury. Indeed, upon reperfusion the active
accumulation of Ca2+ within the mitochondrial matrix due to the rise
in cytosolic Ca2+ can lead to an overload resulting in permeability
transition pore (PTP) opening, mitochondrial depolarization and cell
death [7,8].
In addition to I/R injury, mitochondrial dysfunction is also chieﬂy
involved in the onset and progression of congestive heart failure
(CHF). In this syndrome, cardiac mitochondria display structural
abnormalities and are usually decreased in number [9]. The process
known as mitochondrial biogenesis is responsible for controlling
mitochondrial number and assembly. For instance, a clear functional
correlation has been found between physiological stimuli such as
endurance training and mitochondrial biogenesis accompanying
the increase in cardiac mass [10]. Conversely, the expression of
peroxisome-proliferator-activated receptor gamma coactivator-1α
(PGC-1α), the chief transcriptional coactivator involved in the
regulation of mitochondrial metabolism and biogenesis, is down-
regulated in several models of heart failure [11–16] and in human
failing heart [17]. PGC-1α is also implicated in the regulation of genes
involved in the cellular uptake and mitochondrial oxidation of FAs via
direct co-activation of peroxisome proliferator activated receptors
(PPARs) [18,19]. This phenomenon likely accounts for the “fuel shift”
in substrate preference from FA to glucose, steadily reported in the
failing heart [20–23]. Yet, despite evidence showing that reduced FA
oxidation is a deleterious event associated with heart failure
appearance, early switch from FA to carbohydrate metabolism may
improve cardiac efﬁciency, at least in the short-term [24,25]. Some
animal studies support the view that FA uptake is reduced in failing
hearts, although the few studies done in humans seem to convey
more conﬂicting conclusions [21,26,27]. Thus, whether a shift towards
glucose utilization is a compensatory or maladaptive event remains to
be fully elucidated.
Consistent with the idea of an overall down-regulation of
mitochondrial function in CHF, there is additional evidence
showing that the activity of both respiratory chain complexes
and ATP synthase is lower in this syndrome [28–30]. Accordingly,
the regulation of oxidative phosphorylation by the phosphate
acceptors AMP, ADP and creatine is impaired [31], whereas the
levels of uncoupling proteins (directing the mitochondria to
produce heat rather than ATP) are increased [32]. Hearts from
dogs in which CHF is induced by tachypacing, closely resembling
the adverse features of human end-stage CHF display markedly
reduced activities of respiratory complex III and ATP synthase [33].
A recent study in the same model implies that complexes I and II
might also be involved [34]. The reduction in ATP synthase activity
has been categorized both as an early and persistent event in CHF
development. Another proposed mechanism for mitochondrial
alterations is the decrease in functional respirasomes in heart
failure [35], which in turn should cause a decrease in oxidative
phosphorylation and an increase in electron leakage. Taken
together, these data are of crucial importance considering that
mitochondrial bioenergetics is impaired also in patients with heart
failure [36]. Both ATP and phosphocreatine, the prime cardiac
energy reserve, are reduced in human myocardial infarction [37],
mitochondrial creatine kinase activity is impaired [36] and the
failing human heart has a 25–30% decline in ATP levels as
determined in human biopsy specimens [38].Genetic approach has providedmany additional insights regarding
the pathogenetic role of mitochondria in heart failure. Gene ablation
in mice targeting a wide spectrum of genes encoding speciﬁc
mitochondrial proteins results in severe cardiomyopathy. Adenine
nucleotide translocator knockout mice andmice lacking cytochrome c
oxidase subunit VIa-H both display dilated cardiomyopathy and
severe cardiac ATP deﬁciency [39,40], which is thought to underlie the
resulting cardiac phenotype.
Mitochondria are also involved in intracardiac Ca2+ handling, a key
ion which plays a pivotal role in coordinating changes in cytosolic
workload with mitochondrial energy metabolism in cardiomyocytes.
When the heart has to match an increased demand for blood supply,
Ca2+ is accumulated in mitochondria where it stimulates ATP pro-
duction to cover the rise in energetic expenditures. The modalities/
kinetics of Ca2+ uptake by mitochondria, the extra- and intracellular
factors implicated in its regulation in normal hearts and the possible
changes and functional consequences occurring in CHF have been
recently thoroughly reviewed [41].
2. Reactive oxygen species and myocardial response to stress
A growing body of evidence suggests that reactive oxygen species
(ROS) and oxidative stress may contribute to I/R injury and the
pathogenesis of myocardial remodeling and failure [42–45]. The
pathological consequences of ROS are of major interest, but also not
always fully clariﬁed both in terms of source and modalities of
damage. It is often difﬁcult to dissect between numerous (and
overlapping) signaling pathways mediated by ROS that, in turn,
determine the cell fate. For instance, a number of cascades that
mediate hypertrophic response, matrix remodeling and cellular
dysfunction can be modulated by ROS, which have been demonstrat-
ed to activate a broad variety of hypertrophy signaling kinases and
transcription factors.
Conversely, ROS and reactive nitrogen species can also contribute
to several physiological processes and frequently act as signaling
molecules. In cardiomyocytes, relatively low levels of H2O2 are
known to activate extracellular signal regulated kinase (ERK) 1/2,
p38 and c-Jun N-terminal kinase (JNK) mitogen-activated protein
kinase (MAPK) signaling, protein kinase C (PKC) and PI3 kinases as
well as to stimulate protein synthesis [46]. This combined effect
should favor myocardial survival and compensatory hypertrophy, at
least initially. However, it is known that excess ROS production and/or
limited ROS buffering capacity by resident tissues can fuel myocardial
maladaptive hypertrophy, matrix remodeling and myocyte dysfunc-
tion. For instance, studies have shown that adverse remodeling
induced by angiotensin II (ATII) can be explained by the generation of
H2O2 that in turn activates Ras/Raf/ERK MAPK pathway and the
transcription factor NFκB [46,47]. However, chronic infusion of ATII,
used to induce left ventricular concentric hypertrophy, triggers the
activation of NADPH oxidase (Nox) resulting in a substantial rise
in cardiac superoxide levels [48]. Norepinephrine (NE) interacts with
α- and β-adrenergic receptors and both receptor subtypes have been
implicated in NE-induced ROS generation and hypertrophy [49]. In
neonatal and/or adult rat myocytes, NE increased the level of
intracellular ROS, and this effect could be inhibited by α-adrenergic
receptor blockade, antioxidants or monoamine oxidase (MAO) A
inhibition [49–51]. High levels of H2O2 also stimulate JNK and p-38 to
induce apoptosis [52], thereby likely contributing to ventricular
remodeling via this mechanism. Another MAPK family member
linking ROS, hypertrophy and apoptosis in failing hearts is apoptosis
signal-regulating kinase 1 (ASK-1), a redox-sensitive kinase upstream
of JNK and p-38. ASK-1 activation is a good example illustrating how
an excess of ROS production per se may not be sufﬁcient to trigger an
adverse signaling cascade in the heart. In fact, ASK-1 activation is
tightly controlled by the redox status of thioredoxin 1. Only when
thioredoxin is almost entirely oxidized, thus unveiling a substantial
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cascade of adverse signaling events [53].
ROS also have potent effects on the extracellular matrix,
stimulating cardiac ﬁbroblast proliferation and activating metallo-
proteinases (MMPs) [54–56], effects central to ﬁbrosis and cardiac
remodeling. MMPs are generally secreted in an inactive form and are
activated post-translationally by ROS from targeted interactions with
critical cysteines in the propeptide autoinhibitory domain. In addition
to changes in extracellular matrix composition, bursts of ROS and/or
perturbations of the cellular antioxidant defenses are also responsible
for the alterations of the cardiac contractile machinery, either at the
myoﬁlament or excitation–contraction coupling level [57,58]. This
includes the modiﬁcation of critical thiol groups on the channels,
pumps and transporters implicated in the recruitment and intracel-
lular Ca2+ handling. For instance, transient and reversible redox-
modiﬁcations may increase the open probability of ryanodine
receptor. However, persistent oxidative modiﬁcations may sustain
diastolic Ca2+ leakage, contributing to cardiac arrhythmias and
dampened contractility and/or relaxation [59].
In the setting of I/R injury, cytosolic and mitochondrial Ca2+
overload and ROS accumulation result in the opening of the PTP,
recognized as a major determinant of myocyte injury following I/R
[60,61]. Although PTP opening is particularly sensitive to altered
redox balance [62], its opening and ROS formation are also linked
in a vicious cycle since the latter is exacerbated after PTP opening
in cardiac myocytes [63]. This ampliﬁcation of oxidative stress
targets myoﬁbril proteins resulting in their oxidation and contrac-
tile dysfunction on the one hand [57], and determines the
evolution of cell injury towards necrosis or apoptosis, on the
other [64–67].
3. Sources of oxidative stress
A number of intracellular ROS sources have been identiﬁed in
animal models of cardiac diseases. These include Nox, xanthine
oxidase (XO) and nitric oxide synthase that, when uncoupled, can
become a powerful ROS generator [42,43,68,69]. Concerning XO, it
must be said upfront that in some species, including humans, the
heart appears not to contain any [70,71]. Therefore, an explanation
for the protective effects exerted by the XO inhibitor allopurinol in
these species should be sought elsewhere. For example it is possible
that allopurinol prevents the depletion of purine nucleotides which
can be used as substrates for the resynthesis of ATP on reoxygena-
tion [72].
It is generally accepted that, the largest amount of ROS in cardiac
myocytes is formed within the mitochondria [73–76]. The majority
of oxygen delivered to mitochondria is fully reduced to water at the
level of Complex IV of the respiratory chain. Nevertheless, electrons
ﬂowing through the respiratory chain can be donated to oxygen at
other sites resulting in the formation of partially reduced oxygen
forms, such as superoxide anion. Indeed, superoxide is formed at
the level of Complex I and III and rapidly dismutated into H2O2 by
Mn-SOD. The ﬁnding that Mn-SOD deﬁcient mice develop ROS
toxicity and dilated cardiomyopathy [77], underlines the importance
of ROS in this pathology and of mitochondria as the source and
target of this altered redox equilibrium.
The mitochondrial respiratory chain is certainly the best-
characterized site for ROS generation. Yet, other mitochondrial
proteins, such as p66Shc, MAO and Nox4, are also emerging as major
ROS producers and have potential pathophysiological relevance.
p66Shc localizes partially to mitochondria where it catalyzes electron
transfer from cytochrome c to oxygen [78], a process that can result
in the formation of ROS. Indeed, ROS generation is reduced in cells
lacking p66Shc and in p66Shc−/− mice, whose lifespan is increased
by 30% [78–81]. Furthermore, a lack of p66Shc was shown to protect
against diabetic cardiomyopathy and I/R injury in mice [82]. Asigniﬁcant role for MAO activity in the formation of H2O2 has been
demonstrated in the brain, as MAO have been shown to produce
more H2O2 than the mitochondrial respiratory chain [83]. Indeed,
MAO are involved in numerous neuronal and psychiatric disorders,
as demonstrated by the beneﬁcial effects elicited by MAO inhibitors.
MAO-B seems to be involved in the loss of dopaminergic neurons
that occurs in Parkinson's disease, most likely due to an increased
dopamine catabolism that in turn would result in elevated ROS
production responsible for the oxidative damage of nigrostriatal
neurons [84]. An increase of MAO-B activity in the brain has been
also associated with Alzheimer's and Huntington's disease. Recently,
also Nox4 has been demonstrated to localize primarily in the
mitochondria and to be a major source of oxidative stress in the
failing heart [85,86].
4. MAO as a major source of ROS
4.1. Basic biochemical aspects
MAOs are ﬂavoenzymes located within the outer mitochondrial
membrane, responsible for the oxidative deamination of neurotrans-
mitters and dietary amines. They exist in two isoforms, MAO-A and B,
distinguished by different substrate speciﬁcity and inhibitor sensitiv-
ity. These two enzymes present 70% homology in their primary
sequence [87,88] and both contain the pentapeptide Ser-Gly-Gly-Cys-
Tyr, where the obligatory cofactor FAD is covalently bound through a
thioether linkage to the cysteine residue, namely Cys406 in MAO-A
and Cys397 in MAO-B [89,90]. This ﬂavin moiety is the only redox-
dependent factor necessary for their activity deployment. The 3D
structures of human and rat MAO-A (h/rMAO-A) and human MAO-B
(hMAO-B) have been resolved. Despite their high level of sequence
identity (92%), there are several functional properties that differen-
tiate hMAO-A from rMAO-A. hMAO-A exhibits a 10-fold lower afﬁnity
than rMAO-A for the speciﬁc inhibitor clorgyline [91], and a Phe208 to
Ile mutation onMAO-A from human and rat [92,93] shows differential
effects on activities and sensitivities to irreversible inhibition. The
largest differences among the three known structures of MAO are the
corresponding natures of their oligomeric states: hMAO-B and rMAO-
A are dimers, whereas hMAO-A is a monomer [94]. However, pulsed
electron paramagnetic resonance data showed that this is the case
only in the detergent-solubilized, puriﬁed preparations while all rat
and human MAOs are dimeric in their membrane-bound forms.
MAO-A preferentially catalyzes the oxidative deamination of NE and
serotonin (5-HT) and is inhibited by low concentrations of clorgyline. In
contrast, MAO-B has a major afﬁnity for phenylethylamine and
benzylamine, and is inhibited by selegiline [84]. Both isoforms catalyze
the deamination of dopamine, tyramine, octopamine and tryptamine
and are inhibited by pargyline.
The prototypic reaction catalyzed by MAO is the following:
RCH2NR
′R″ + O2 + H2O→RCHO + NR
′R″ + H2O2:
Kinetic studies have shown that the binding of the amine group to
the enzyme precedes the binding of oxygen [95]. In the ﬁrst moment,
the reduction of the cofactor FAD yields an aldehyde intermediate and
ammonia, while in the second moment the oxidized form of the
prosthetic group is restored with the concomitant production of H2O2.
The aldehyde intermediate is rapidly metabolized to corresponding
acid by the action of aldehyde dehydrogenase.
RCH2NH2 + MAO→RCHO + NH3 + MAO−reduced
MAO−reduced + O2→MAO + H2O2:
The distribution of MAO in various tissues of different species
has been investigated through use of speciﬁc inhibitors,
MAO activation
Increased H2O2 production
ERK1/2 NFAT3/4 MMPs Bax SphK
inhibition
Hypertrophy
Cell proliferation
Matrix remodeling
Mitochondrial dysfunction
Apoptosis/Necrosis
Post-ischemic reperfusion injury
Heart failure
Oxidation of
myofibrillar proteins
Fig. 1. Signaling pathways triggered by MAO-induced H2O2 formation. Increased H2O2
production byMAO can trigger different signaling pathways in different cell types. Lower
levels of H2O2 activate ERK1/2, NFAT3/4 and MMPs in cardiac myocytes and vascular
smooth muscle cells resulting in hypertrophy, cell proliferation and matrix remodeling.
Instead, higher levels of MAO activity are associated with Bax up-regulation, SphK
inhibition, myoﬁbrillar oxidation and mitochondrial dysfunction leading to cell death in
heart failure or following ischemia/reperfusion. MAO: monoamine oxidase, ERK:
extracellular signal regulated kinase, NFAT: nuclear factor of activated T cells, MMPs:
metalloproteinases, SphK: sphingosine kinase.
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bridization [96–98]. MAO location has been intensively studied
particularly in the brain, where MAO-A has been prevalently found
in noradrenergic neurons, whereas MAO-B has been detected in
serotoninergic and histaminergic neurons and in glial cells [99–
102]. In peripheral tissues, MAO-A has been found in the placenta,
liver, intestine and thyroid gland, while platelets, liver and kidney
contain mainly MAO-B. Human cardiomyocytes contain both
enzymes, although MAO-A appears to be the predominant isoform
[103,104].
4.2. The physiological role of MAOs
The main physiological role of MAO is the degradation of
endogenous monoamine neurotransmitters and dietary amines, such
as tyramine. In peripheral tissues, MAO are involved in the oxidative
catabolism of amines from the blood and in preventing the entry of
dietary amines into the circulation. In the central andperipheral nervous
system, intraneuronal MAO-A and -B protect neurons from exogenous
amines, terminate the actions of amine neurotransmitters and regulate
the contents of intracellular amine stores.
From a different angle, studies employing selective pharmacolog-
ical MAO inhibition and its genetic ablation have further delineated
their physiological roles. Deletion of MAO-A and MAO-B genes has
proven their important roles in neurotransmitter metabolism and
behavior. MAO-A knockout mice have elevated brain levels of 5-HT,
NE and, to a lesser extent, dopamine [105]. Conversely, only 2-
phenylethylamine is increased in MAO-B knockout mice [84]. Both
MAO-A and -B knockout mice show increased reactivity to stress,
similar to that observed after administration of non-selective MAO
inhibitors. In humans, MAO-A deﬁciency results in borderline mental
retardation and impaired impulse control, whereas a lack of MAO-B
doesn't lead to intellectual impairment or behavioral disturbances
[106]. Deletion of both genes in a male patient has been shown to
cause a profound mental retardation, severe developmental delay,
intermittent hypotonia and stereotypical hand movements [107].
Although these studies indicate that MAO is not essential for survival,
gene deletion approaches have proven that MAO-A activity is
important during neuronal development. A compulsive–aggressive
behavior resulting from lack of MAO-A function in humans and mice
[108,109] might reﬂect the importance of 5-HT during development
and can be mimicked by the administration of the MAO-A inhibitor
clorgyline during the early postnatal period. Studies of MAO-A
knockout mice have also shown the maintenance of 5-HT levels to
be important for the normal development of thalamocortical axons
and the aggregation of neurons to form barrels [110].
The roles of MAO in terminating the actions of neurotransmitters/
dietary amines in central and peripheral nervous system and in the
extraneuronal tissue have been extensively studied. In contrast, much
less attention has been dedicated to the products of their activity. The
monoamine catabolism byproducts are aldehydes, ammonia and
H2O2, a reactive oxygen species that could be toxic per se at high
concentrations or it could generate hydroxyl radical when in the
presence of free Fe2+. Aldehyde intermediates are also toxic for the
biological systems and a decrease in aldehyde dehydrogenase activity,
which is associated with oxidative stress [111], might further
contribute to the exacerbation of damage. These are the aspects of
MAO biochemical and pharmacological proﬁles that certainly deserve
further attention.
5. MAO in cardiac pathophysiology
5.1. MAO in hypertrophy and heart failure
Despite their wide distribution in animal and human organs/
tissues and their association with mitochondria, the role of MAOs hasbeen primarily investigated in the central and peripheral nervous
system or in the gastro-intestinal tract. It is only recently that the
cardiovascular ﬁeld has focused on the role of MAO activity in the
heart, with much of the pioneering work performed by Parini's group.
This research team was the ﬁrst to demonstrate the role of MAO-A as
an important myocardial source of ROS. Depending on the concentra-
tions of the available substrate, ROS produced by MAO-A are able to
trigger separate signaling pathways leading respectively to cell
proliferation and hypertrophy or apoptosis [112] (Fig. 1). In one
study, Bianchi and coworkers demonstrated that low concentrations
of 5-HT are able to induce cardiomyocyte hypertrophy in a MAO-A
dependent manner, involving activation of ERK1/2, an essential
signaling molecule for cell growth [113]. The use of pharmacological
inhibitors demonstrated that hypertrophy induced by 5-HT involves a
dual action by both receptors and MAO-A. Indeed, in vascular smooth
muscle cells 5-HT1B/D receptor stimulation induced ERK phosphory-
lation, whereas H2O2 generated by MAO was responsible for ERK
translocation into the nucleus [112]. In addition to 5-HT, in vitro
studies from our group have also recently unraveled a major role for
MAO-A in NE-induced hypertrophy [51]. Using neonatal rat and adult
mouse cardiomyocytes, we have found that NE acts in part
independently from α- or β-adrenergic receptor binding. Employing
a pharmacological and genetic approach, we showed that NE induced
hypertrophy is also partially mediated by MAO-A generated ROS
through a mechanism likely involving nuclear factors of activated T
cells 3 and 4, transcription factors involved in maladaptive hypertro-
phic signaling. Furthermore, we have demonstrated that the stimu-
lation of MAO-A activity is sufﬁcient to trigger myocyte hypertrophy,
independently of receptor activation.
The important role of MAO in the transition from compensated
hypertrophy to heart failure was demonstrated by in vivo studies.
MAO-A expression and activity increase in rats with aging [114], a
condition often associated with heart failure. Similarly, MAO-B
expression is elevated in the myocardium of dogs in which CHF was
induced by tachypacing [115]. However, these studies did not
correlate changes in MAO activity with alterations in cardiac function.
This possible causative relationship was examined in mice in which
CHF was induced by pressure overload due to transverse aortic
constriction (TAC). In these hearts NE degradation by MAO-A was
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Pharmacological or genetic inhibition of MAO-A in this CHF model
conﬁrmed its central role as amajor in vivo trigger of cardiac oxidative
stress, left ventricle (LV) remodeling and apoptosis. Indeed, both
approaches, while blunting excess ROS production, completely
prevented LV dilation and pump dysfunction in these chronically
stressed hearts. It is also worth mentioning that the use of clorgyline
normalized the protein abundance of the neuronal NE transporter,
and likely ameliorated its function resulting in an improved NE
bioavailability and cycling. Thus, clorgyline which has no major
cardiac impact on sham-operatedmice has been shown to beneﬁt TAC
hearts through at least two mechanisms. One is through the reduction
in ROS burden, therefore countering the adverse structural and
functional sequelae of increased oxidative stress. Indeed, triggering
H2O2 formation from MAO-A results in the activation of MMPs and LV
remodeling. Moreover, this excess in H2O2 production can also target
mitochondria themselves, resulting in the ampliﬁcation of the oxidativeHypertrophic stimuli/Neurohorm
RIRR
Mitochondrial dysfunct
Left Ventricular Remod
and Dysfunction 
O2 H2O2
Fig. 2. Mechanism for MAO activation and consequent mitochondrial dysfunction in heart f
overload) results in increased availability of catecholamines for MAO-mediated degradatio
remodeling and myocardial function, but it may also target mitochondria resulting in perme
the damage in the heart. It should not be excluded that other products of MAO activity, sucstress, mitochondrial dysfunction, PTP opening, release of cytochrome c,
caspase activation and apoptosis (Fig. 2). Some of these deleterious
events occurred in TAC hearts, but were almost completely abated by
MAO-inhibition via clorgyline. The other mechanism concerns the
rescued levels of available neuronal NE pool, denoting an improved
catecholamine cycling.
In an apparent contrast to the studies mentioned above, Lairez
and colleagues have observed exacerbated ventricular hypertrophy
in MAO-A knockout mice subjected to aortic banding, and have
attributed this effect to the hyperactivation of 5-HT2A receptors in
MAO-A knockout mice [116]. This discrepancy might be explained
by some adaptive mechanisms present in the knockout mice (such
as overexpression of 5-HT2A receptors, increased catecholamine and
5-HT content) and by the fact that the experimental observations
performed in this study were limited to the compensated
hypertrophy time-frame and not extended to later stages in
which left ventricular dilation and pump failure is evident.onal activation 
ion
eling
? ?(+)
Aldehydes Ammonia
ailure. Hyperadrenergic activation following a hypertrophic stimulus (such as pressure
n. This in turn leads to elevated H2O2 formation that can directly inﬂuence ventricular
ability transition pore opening and ROS induced ROS release (RIRR), further amplifying
h as aldehydes and ammonia, may also participate to these processes.
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activity is a major contributing factor for the development of
pathologic hypertrophy and heart failure, at least in rodents.
Intriguing enough is the ﬁnding that MAO-A expression is elevated
in pathological hypertrophy and heart failure in rats, but not in
physiological hypertrophy induced by exercise [117]. It goes
without saying that many additional, fundamental questions follow.
First and foremost, what are the signaling cascades that activate
MAO-A expression/activity in adverse cardiac remodeling? Second,
are these same pathways silent in hearts subjected to physiological
stress as such exercise? And if so, why? Another important
question that begs future attention is whether the oxidative stress
present in CHF models such as pressure overload is due to MAO
activation alone or also due to other sources. A cross-talk between
MAO, mitochondrial respiratory chain, Nox4 or p66Shc is likely and
could result in the ampliﬁcation of the oxidative stress. However,
there is not enough evidence in the literature at the moment to
link these processes together and/or to attribute relative impor-
tance to one or another source. Further studies addressing these
basic unknowns will greatly help to consolidate our understanding
on the contribution of each of these components to CHF
development.
Data remain very scant on the possible involvement of MAO-B in
this setting. Despite the fact that the role of MAO-A in myocardial
failure is better described, the potential contribution of MAO-B should
not be disregarded as it appears to be up-regulated in some
experimental models of CHF. The relative expression of each MAO
isoform varies enormously across different tissues and species. For
instance, MAO-A is the predominant isoform in the rat heart, with
little or no MAO-B activity, whereas exactly the opposite is true in the
case of themousemyocardium [118]. Themajority of the studies were
performed in rats, therefore highlighting the deleterious effects of
MAO-A derived ROS. Interestingly though, speciﬁc MAO-A inhibition
in mouse hearts subjected to pressure overload is able to completely
prevent oxidative stress, apoptosis, LV dysfunction and remodeling
[51]. The involvement of speciﬁc MAO substrates might count as a
partial explanation for this observation. However, it is also tempting
to speculate that each isoform might be differently expressed in
distinct cell types where the consequences of increased oxidative
stress can determine separate outcomes. Further studies are necessary
to explore this possibility.
5.2. MAO in I/R injury
Although lower 5-HT concentrations promote cell proliferation,
survival and hypertrophy, higher 5-HT concentrations lead to
cardiomyocyte apoptosis. This effect can be entirely attributed to
MAO-A activation as apoptosis was completely blocked by the MAO
inhibitor pargyline with the 5-HT2B antagonist failing to inhibit this
response [119]. ROS generated byMAO in the presence of elevated 5-HT
concentrations induced release of cytochrome c, up-regulation of
proapoptotic Bax and down-regulation of antiapoptotic Bcl-2 proteins
[119]. These in vitro ﬁndings pertain to in vivo pathophysiological
situations because I/R injury is associated with increased interstitial
5-HT released by activated platelets [120]. Therefore, a role for MAO-A
is plausible. Indeed, in an in vivo rat model of I/R injury, infarct size was
dramatically reduced in animals treated with pargyline or clorgyline
prior to I/R as compared tountreated rats [119]. However, another study
performed in isolated Langendorff perfused mouse hearts showed that
MAO inhibition by pargyline is equally effective in preventing I/R
induced injurydespite the fact that 5-HTwas absent in thatmodel [121].
Although the role of MAO remains central in mediating I/R injury, the
importance of 5-HT as a major MAO substrate warrants further
investigation.
MAO-A generated ROS in I/R induce sphingosine kinase inhibi-
tion, ceramide accumulation and sphingosine-1-phosphate (S1P)degradation in cardiac myocytes thereby leading to mitochondria-
mediated apoptosis [122]. This is yet another interesting example of
the dual role of ROS in the regulation of cell proliferation, survival
and cell death; the control of the sphingolipid rheostat (sphingo-
stat), the dynamic balance between the S1P and ceramide, by MAO-
A and the consequent regulation of opposing signaling pathways
that ultimately determine the cell fate. In the smooth muscle cells,
oxidation of low concentrations of 5-HT or tyramine by MAO-A
triggers MMP2, neutral sphingomyelinase-1 and sphingosine kinase
resulting in cell proliferation [123]. Considering that MAO-A controls
the activity of sphingosine kinase that, in turn, controls the levels of
both proapoptotic ceramide and antiapoptotic S1P, it may be an
important drug target for regulating I/R injury in the heart and
vascular wall remodeling.
6. The therapeutic potential of MAO inhibitors
Despite the fact that experimental studies strongly support a key
role of oxidative stress in the pathophysiology of I/R injury and
heart failure, the outcome of clinical trials using different antiox-
idant approaches remains disappointing. There is no doubt that
some drugs already in use for CHF treatment may act indirectly to
ameliorate excessive oxidative stress. This is the case of angioten-
sin-converting enzyme inhibitors and AT receptor blockers that may
reduce G protein-linked signaling through Nox. Likewise, β-blockers
may provide some beneﬁts as β-adrenergic receptor activation is
coupled to the generation of ROS [124]. In addition, drugs such as
carvedilol or nebivolol may have additional antioxidant properties
independent of the β-blocking effect [125,126], whereas drugs such
as statins and hydralazine have indirect inhibitory effects on ROS
production [127]. As hinted before, the beneﬁcial effects observed in
animal CHF models with XO inhibitors such as allo- or oxy-purinol
were not reproduced in humans [128]. Finally, large clinical trials of the
antioxidant vitamins A and E and their precursors have been
disappointing [129,130]. Conversely, ubiquinone, an antioxidant,
caused a small but signiﬁcant increase in ejection fraction in a meta-
analysis of 11 randomized clinical trials [131]. Considering these results,
it is possible that more speciﬁc targeting of the sources of oxidative
stress may ultimately provide more effective approaches to reversing
cardiac remodeling.
6.1. MAO inhibitors
The investigation of the therapeutic potential of MAO inhibitors
started in the early '50s as anti-tuberculosis treatment with iproniazid
was shown to improve the mood and inhibit MAO activity. Nowadays,
there is a wide range of MAO inhibitors at our disposal, and this class
of drugs has been proven effective against many diseased states
including affective disorders, neurodegenerative diseases, stroke and
eugeric aging. Just to provide a brief census of them, they can be
classiﬁed in three major groups based on their speciﬁcity for each
isoform and by the nature of their binding to the enzyme [84]. There
are:
- Irreversible and nonselective inhibitors, such as phenelzine and
tranylcypromine;
- Irreversible and selective inhibitors, such as selegiline for MAO-B
and clorgyline for MAO-A;
- Reversible and selective MAO-A inhibitors (RIMAs), such as
moclobemide.
All the irreversible MAO inhibitors form N(5) ﬂavin adducts, with
the exception of tranylcypromine that forms the ﬂavin C(4a) adduct
with MAO-B [94]. Differences in inhibitor speciﬁcity are due to
distinct architecture of the active sites between the two isoenzymes.
The active site cavity of MAO-B is bipartite and determined by the
1329N. Kaludercic et al. / Biochimica et Biophysica Acta 1813 (2011) 1323–1332conformation of Ile199 that functions as a gating residue and may
result in a closed or open conformation. The corresponding residue in
human and rat MAO-A is Phe208, but the bulky side Phe chain
impedes such conformational ﬂexibility, reduces the space of the
entrance cavity and therefore interferes with the binding of speciﬁc
MAO-B inhibitors [94]. hMAO-B can bind compounds of different
sizes; depending on the conformation of gating residue Ile199, the
cavity can host either small inhibitors or cavity-ﬁlling ligands.
Therefore, small compounds such as isatin and tranylcypromine
show similar binding afﬁnities for both isoforms, whereas cavity-
ﬁlling ligands, such as saﬁnamide, are highly speciﬁc for MAO-B [94].
6.2. Current use for MAO inhibitors
MAO inhibitors have been used for decades for the treatment of
depression [84]. The antidepressant properties result from selective
MAO-A inhibition in the central nervous system, which leads to
increased brain levels of dopamine, NE and 5-HT. Some of the non-
selective irreversible inhibitors, such as isocarboxazide, phenelzine
and tranylcypromine, are still in clinical use for the treatment of mood
disorders, along with the reversible MAO inhibitors moclobemide and
toloxatone. As levels of MAO-B are increased in patients with
Parkinson's disease, the MAO-B inhibitor selegiline is used as a
dopamine sparing agent or as adjunct to L-DOPA and has been shown
to be effective both as an adjuvant to L-DOPA and as monotherapy
[84]. Recently, a new MAO-B inhibitor rasagiline has been commer-
cialized for the treatment of the symptoms of Parkinson's disease.
Combination of MAO-B inhibitor with cholinesterase inhibitor is
beneﬁcial for the treatment of Alzheimer's disease [132]. Selegiline
has also been shown to reduce the peripheral tissue damage that
results from cardiac failure [133], and that arising in the brain
after cerebral ischemia [134] in animal models. This protective effect
has been attributed to a decrease in hydrogen peroxide production
generated by MAO upon reperfusion. Selegiline has also been
shown to increase Bcl2 to Bax ratio and activate the translocation of
anti-apoptotic protein kinases, PKCα and PKCε [135], although the
mechanisms leading to these effects are as yet not completely
elucidated. A protective outcome following selegiline treatment
have also been observed at concentrations lower than those required
for MAO-B inhibition, suggesting that they may be independent of
MAO-B inhibition.
It should be pointed out that non-selective, irreversible MAO
inhibitors might cause adverse reactions when taken together with
drugs such as sympathomimetics, in case of hypertension or when
taken in combination with cheese or other foods particularly rich in
tyramine content. These combinations cause hypertensive crises
(the so-called “cheese reaction”) that may result even in sudden
death. For decades, this side-effect was the major drawback for the
use of MAO inhibitors in clinic. However, non-reversible MAO-B
inhibitors and RIMAs are devoid of these undesirable effects and can
be used by patients on unrestricted diet [136]. Thus, considering the
availability of these amenable inhibitors and the encouraging results
obtained with MAO inhibitors in experimental CHF and I/R injury,
MAO inhibition might represent a potential new class of compounds
to employ for treatment of ischemic and nonischemic cardiac
disorders. Along this line, it would be interesting to test the
hypothesis that patients treated with MAO inhibitors experience a
lower incidence of cardiac injury, especially myocardial infarction.
In this respect, it is worth mentioning that at the moment there are
no data available concerning the role of MAO-derived oxidative
stress related to atherosclerosis. However, MAO could be implicated
also in chronic vascular alterations considering that a tight link
between mitochondrial ROS formation and vascular injury has been
demonstrated [137].
Very often, “old mates” make surprises. Therefore, we hope that
focusing our attention on these mitochondrial companions will leadus to learn increasingly more on the role of certain disturbances such
as myocardial tissue redox imbalance and altered communication
between the peripheral nervous system and the cardiac muscle in
acute and chronic heart pathobiology. This in turn will allow us to
enrich our therapeutic armamentarium against many chronic and
severely invalidating cardiac conditions such as CHF.
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